Heart drug mavacamten under the microscope: Real-World study launches
NCT ID NCT07557498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is following about 362 adults with a type of heart disease called obstructive hypertrophic cardiomyopathy who are taking the drug mavacamten. Researchers want to see how the drug works in real doctor's offices, not just in strict research settings. They will track things like blood pressure, heart function, and how patients and their doctors feel about the treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Adelphi Real World
RECRUITINGBollington, Macclesfield, SK10 5JB, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New heart drug aficamten challenges standard Beta-Blocker in major trial
- Heart drug mavacamten shows promise in Real-World study
- Gene test may personalize heart drug dosing
- New pill aims to help heart patients breathe easier and move more
- Heart drug mavacamten under real-world safety watch in japan
- Could a common supplement help hearts pump better?